Cevimeline是一种强效的直接作用muscarinic受体激动剂，具有口服生物利用度。
Cas No.:107233-08-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Cevimeline is a potent direct-acting muscarinic receptor agonist with oral bioavailability [1]. Cevimeline can bind and activate M1 and M3 muscarinic receptors, and can cross the blood-brain barrier (BBB) to positively influence tau pathology and reduce the levels of amyloid-β (Aβ) peptide [2]. Cevimeline has been widely used to enhance the function of salivary glands and to increase the excitability of neurons in animal models[3].
In vitro, Cevimeline (10µM) treatment for 2 minutes significantly increased the calcium ion concentration within the rat parotid gland cells[4].
In vivo, Cevimeline treatment via oral administration at a dose of 10mg/kg/day for 7 days restored the level of AQP5 protein in the submandibular gland of rats, which had been decreased by parasympathectomy [5]. Oral administration of Cevimeline three times a day at a dose of 9mg/kg for 2 weeks reversed olanzapine-induced body weight gain and decreased feeding efficiency in female rats[6]. A single intraperitoneal injection of 10mg/kg dose of Cevimeline for 20 minutes significantly induced salivary secretion in diabetic mice and increased amylase activity[7].
References:
[1] Ono M, Takamura E, Shinozaki K, et al. Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study[J]. American journal of ophthalmology, 2004, 138(1): 6-17.
[2] Oleksak P, Novotny M, Patocka J, et al. Neuropharmacology of cevimeline and muscarinic drugs—focus on cognition and neurodegeneration[J]. International Journal of Molecular Sciences, 2021, 22(16): 8908.
[3] Ueda H, Mitoh Y, Ichikawa H, et al. Cevimeline enhances the excitability of rat superior salivatory neurons[J]. The Journal of Medical Investigation, 2009, 56(Supplement): 267-269.
[4] Ono K, Inagaki T, Iida T, et al. Distinct effects of cevimeline and pilocarpine on salivary mechanisms, cardiovascular response and thirst sensation in rats[J]. Archives of oral biology, 2012, 57(4): 421-428.
[5] Li X, Azlina A, Karabasil M R, et al. Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by cevimeline, an M3 muscarinic receptor agonist[J]. American Journal of Physiology-Gastrointestinal and Liver Physiology, 2008, 295(1): G112-G123.
[6] Lian J, Deng C. The dosage-dependent effects of cevimeline in preventing olanzapine-induced metabolic side-effects in female rats[J]. Pharmacology Biochemistry and Behavior, 2020, 191: 172878.
[7] ISHII H, NAKAGAWA Y, SHIGA T, et al. Effects of Cevimeline hydrochloride on salivary secretion in streptozotocin-induced diabetic Balb/cA mice[J]. ORAL THERAPEUTICS AND PHARMACOLOGY, 2001, 20(2): 86-91.
Cevimeline是一种强效的直接作用muscarinic受体激动剂，具有口服生物利用度[1]。Cevimeline能够结合并激活M1和M3 muscarinic受体，并能穿过血脑屏障（BBB），对tau蛋白病理产生积极影响，并降低amyloid-β (Aβ)肽的水平[2]。Cevimeline已被广泛用于增强唾液腺功能，并用于增加动物模型中神经元的兴奋性[3]。
在体外，使用10μM的Cevimeline处理大鼠腮腺细胞2分钟，显著增加了细胞内的钙离子浓度 [4]。
在体内，每日口服10mg/kg剂量的Cevimeline，连续7天，恢复了因副交感神经切除而降低的大鼠颌下腺中AQP5蛋白水平[5]。每日三次口服9mg/kg剂量的Cevimeline，持续2周，逆转了olanzapine诱导的雌性大鼠体重增加和摄食效率降低[6]。单次腹腔注射10mg/kg剂量的Cevimeline持续20分钟，显著诱导了糖尿病小鼠的唾液分泌，并增加了淀粉酶活性[7]。
| Cell experiment [1]: | |
Cell lines | Rat parotid gland cells |
Preparation Method | Rat parotid gland cells were immediately removed from deep anaesthesia of rats and placed in cold balanced salt solution (BSS) containing: 120mM NaCl, 5mM KCl, 1mM Na2HPO4, 2mM CaCl2, 1mM MgCl2, 10mM glucose, 20mM HEPES (adjusted to pH 7.4 by NaOH), and 0.5% bovine serum albumin. After mincing, the material was then digested for 30min at 37 °C with 50U/ml collagenase in BSS, and the suspension was gently passed through a pipette 10 times every 10min. After filtering through a 150μm nylon mesh, the cell preparations were loaded with 2μM fura-2AM, which was suspended in 10ml of BSS, and incubated for 30min at room temperature. After dispersing the cell preparation on poly-d-lysine-coated glass-bottom dishes, the dishes were mounted on the stage of an inverted fluorescence microscope and perfused with BSS at a rate of 1ml/min at 36 °C. The excitation of fura-2 was induced every second by an alternate illumination of 340 and 380nm light, and the resultant fluorescence (510-550nm) was collected using an objective lens and a silicon-intensified target camera. Different concentrations of Cevimeline (0, 1, 10, and 100µM) were applied to cells by superfusion. Record the calcium ion concentration data every two minutes. |
Reaction Conditions | 0, 1, 10, and 100µM; 2min |
Applications | Cevimeline treatment dose-dependently increased the calcium ion concentration within the rat parotid gland cells. |
| Animal experiment [2]: | |
Animal models | Male Sprague-Dawley rats |
Preparation Method | Male Sprague-Dawley rats (7 weeks old), weighing 170-190g, were kept in temperature-controlled (21°C-25°C) and humidity-maintained (40%-70%) rooms with a 12-h light/dark cycle. Water and food were provided freely. Cervical sympathetic trunk denervation (CSTD) or chorda tympani denervation (CTD) were performed under anesthesia with pentobarbital sodium (50mg/kg). Cevimeline (10mg/kg; p.o.), pilocarpine (0.3mg/kg; p.o.), or chloroquine diphosphate (50mg/kg; p.o.) was administered every day for 7 days starting from the 15th day after the operation. On the 21st day after the operation, the rats were killed and the submandibular glands were immediately dissected to determine AQP protein and mRNA levels. |
Dosage form | 10mg/kg/day for 7 days; p.o. |
Applications | Cevimeline treatment enhanced the levels of AQP5 protein and mRNA in the submandibular glands of rats after parasympathectomy. |
References: | |
| Cas No. | 107233-08-9 | SDF | |
| 别名 | 西维美林; AF102B | ||
| 化学名 | (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] | ||
| Canonical SMILES | CC1OC2(CN3CCC2CC3)CS1 | ||
| 分子式 | C10H17NOS | 分子量 | 199.32 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.0171 mL | 25.0853 mL | 50.1706 mL |
| 5 mM | 1.0034 mL | 5.0171 mL | 10.0341 mL |
| 10 mM | 501.7 μL | 2.5085 mL | 5.0171 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet